BASI Bioanalytical Systems Inc

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

On March 17, 2022, at the annual meeting of shareholders of Inotiv, Inc. (the “Company”), the shareholders of the Company approved an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan (the “Equity Plan”). The amendment consists of the removal from Section 4.3 of the Equity Plan of certain limitations on the number of stock options, stock appreciation rights, shares of restricted stock and restricted stock units that could be awarded to an employee participant in any fiscal year.

​

As previously reported, the Company’s Board of Directors approved retention and annual incentive grants of restricted stock units (“RSUs”) to Robert W. Leasure, Jr., the Company's President and Chief Executive Officer. The RSUs granted as Mr. Leasure's retention award and the RSUs in excess of 42,429 granted as part of Mr. Leasure's annual incentive award were subject to the approval of the amendment to the Equity Plan by the Company’s shareholders at the annual meeting.  As a result of such approval, 349,315 additional RSUs were granted to Mr. Leasure effective March 17, 2022.

​

A more complete description of the terms of the Equity Plan, including the amendment, can be found in “Proposal 3 – Amendment of the Amended and Restated 2018 Equity Incentive Plan” in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on February 3, 2022. The foregoing summary of the Equity Plan and the amendment is qualified in its entirety by reference to the full text of the Equity Plan, as amended, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

.

​